More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$158.84B
EPS
6.12
P/E ratio
39
Price to sales
6.15
Dividend yield
0.709%
Beta
0.737156
Previous close
$229.91
Today's open
$228.49
Day's range
$225.07 - $231.30
52 week range
$160.93 - $242.80
show more
CEO
Julie Sawyer Montgomery
Employees
60000
Headquarters
Washington, DC
Exchange
New York Stock Exchange
Shares outstanding
703530815
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Danaher Targets Faster Growth With Acquisitions, AI and a Diagnostics Push
Danaher NYSE: DHR is focusing on commercial execution, innovation and acquisitions as it seeks faster core growth and market-share gains, company leader Julie said during a discussion with Tycho Peterson of the Life Science team.
MarketBeat • 16 hours ago

Danaher Corporation (DHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Danaher Corporation (DHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

VTRS or DHR: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research • Nov 10, 2026

Danaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in Focus
Danaher NYSE: DHR President and CEO Julie Sawyer Montgomery said the company is aiming for faster core growth and market share gains through stronger commercial execution, innovation and acquisitions, as it pursues a leadership position in life sciences and diagnostics.
MarketBeat • Nov 10, 2026

Danaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference Transcript
Danaher Corporation (DHR) Presents at 2026 UBS Global Healthcare Conference Transcript
Seeking Alpha • Nov 9, 2026

Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences
WASHINGTON, Nov. 2, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Julie Sawyer Montgomery, will be presenting at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 9, 2026 at 11:45 a.m. ET and Jefferies Global Healthcare Conference in London, UK on November 17, 2026 at 10:00 a.m.
PRNewsWire • Nov 2, 2026

Danaher (DHR) Upgraded to Buy: Here's Why
Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Oct 27, 2026

Danaher Q3 Recap: Decent Results, Still A Hold
Danaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.
Seeking Alpha • Oct 22, 2026

LH vs. DHR: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Zacks Investment Research • Oct 22, 2026

Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
Danaher Corp. (NYSE:DHR) on Wednesday reported third-quarter adjusted earnings of $2.11 per share, beating the analyst consensus estimate of $1.92.
Benzinga • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Danaher Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.